BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
Biovest International Inc (a subsidiary of Accentia BioPharmaceuticals Inc), under license from Stanford University, is developing BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas that, in combination with GM-CSF, exclusively targets cancerous B-cells by raising an immune response to tumor-specific immunoglobulin proteins called idiotypes, for the potential treatment of follicular non-Hodgkin's lymphoma (NHL). Phase I and II clinical trials demonstrated the immunogenicity, safety and therapeutic efficacy of BiovaxID. Phase III clinical trials in NHL were ongoing at the time of publication.
Reinis
Milan
M
Institute of Molecular Genetics AS CR, vvi, Vídenská 1083, Prague 4, CZ-14220, Czech Republic. reinis@img.cas.cz
D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy*; D051379:Mice; D014611:Vaccination / Q000379:methods
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor